You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中基長壽科學(00767.HK)擬攜手青島黃海醫藥成立合資 重點開展防癌早篩及長壽醫學檢測等業務
格隆匯 05-11 23:00

格隆匯5月11日丨中基長壽科學(00767.HK)公吿,於2021年5月11日,公司與青島黃海醫藥經營有限公司("青島黃海醫藥")訂立合作協議,據此,雙方擬作為共同投資人出資註冊成立有限責任公司。

合資公司其中,公司持有51%股權,黃海醫藥持有49%股權,合資公司註冊地擬定為青島。合資公司未來將與公司及香港先進醫療機構合作,擬重點開展防癌早篩、長壽醫學檢測、免疫細胞存備服務,經銷長壽膳食補充劑、提供長壽諮詢管理服務、長壽解決方案等業務。雙方合作自合作協議簽署日起生效,90日內完成合資公司的註冊登記,並開始投資運營。

青島黃海製藥有限責任公司("黃海製藥")是青島市最大的綜合性專業製劑企業,在業內享有很高的聲譽。成立於1959年,公司位於青島市高新區,佔地面積200餘畝,600多名員工,產品以緩控釋製劑為主線,涵蓋片劑、膠囊劑、口服液製劑、小容量注射劑等劑型100多個品種和規格,主要產品有伲福達、硝酸異山梨酯緩釋片、麥特美、元順、新速效感冒片、複方甘草合劑等。主導產品伲福達先後榮獲"青島市名牌產品"、"山東省名牌產品"稱號,市場佔有率高達70%以上。

青島黃海醫藥是黃海製藥的全資子公司,負責黃海製藥全部產品的銷售工作,2019年黃海製藥銷售額超過15億元人民幣。兄弟企業有青島黃海足球俱樂部,青島黃海生物製藥有限公司,青島黃海健康體檢中心等。

董事會相信成立合資公司可進一步完善集團全球長壽科學領域的佈局,拓展優勢資源,強強聯合,優勢互助,長遠為集團帶來穩定、持續增長收入。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account